New hope for hard-to-treat stomach cancer: drug combo shows promise
NCT ID NCT06085755
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study tests a combination of two targeted drugs, trastuzumab deruxtecan (T-DXd) and afatinib, in people with advanced HER2-low stomach cancer that has not responded to prior treatments. About 61 adults will take part to see if the combination is safe and can shrink tumors or slow the disease. The goal is to improve outcomes for a cancer type with limited treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.